Oral Microbiology and Immunology

Short communication

Down-regulation of interleukin-1 α -induced matrix metalloproteinase-13 expression via EP₁ receptors by prostaglandin E₂ in human periodontal ligament cells

Noguchi K, Ruwanpura SMPM, Yan M, Yoshida N, Ishikawa I. Down-regulation of interleukin-1 α -induced matrix metalloproteinase-13 expression via EP_1 receptors by prostaglandin E_2 in human periodontal ligament cells. Oral Microbiol Immunol 2005: 20: 56–59. © Blackwell Munksgaard, 2005.

In the present study, we investigated the effect of prostaglandin (PG) E_2 on matrix metalloproteinase (MMP)-13 production in human periodontal ligament cells stimulated with interleukin (IL)-1 α . IL-1 α enhanced both MMP-13 and PGE₂ production. Indomethacin, a nonselective cyclooxygenase inhibitor, and NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, significantly enhanced IL-1 α -induced MMP-13 production in periodontal ligament cells, although both the agents completely inhibited IL-1 α -induced PGE₂ production. Exogenous PGE₂ reduced IL-1 α -induced MMP-13 mRNA and protein production in a dose-dependent manner. 17-phenyl- ω -trinor PGE₂, a selective EP₁ receptor agonist, mimicked the inhibitory effect of PGE₂ on IL-1 α -induced MMP-13 mRNA and protein production. On the basis of these data, we suggest that COX-2-dependent PGE₂ down-regulates IL-1 α -elicited MMP-13 production via EP₁ receptors in human periodontal ligament cells. PGE₂ may be involved in the regulation of destruction of extracellular matrix components in periodontal lesions.

K. Noguchi¹, S. M. P. M. Ruwanpura¹, M. Yan^{1,2}, N. Yoshida³, I. Ishikawa¹ ¹Periodontology, Department of Hard Tissue Engineering, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Pediatric Dentistry, The First School of Medicine, Harbin Medical University, Harbin, China, ³Department of Dental Hygiene, Shizuoka College, University of Shizuoka, Shizuoka, Japan

Key words: EP receptors, interleukin- 1α ; matrix metalloproteinase-13; periodontal ligament cells; prostaglandin E₂

Kazuyuki Noguchi, Department of Hard Tissue Engineering, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113–8549, Japan Tel.: +81 35803 5488; fax: +81 35803 0196; e-mail: kazuyuki-noguchi.peri@tmd.ac.jp Accepted for publication August 11, 2004

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteases that degrade extracellular matrix (1). MMP-13 (collagenase-3) cleaves fibrillar collagen over types I and III, and have 40-fold stronger gelatinase activity than MMP-1 (collagenase-1) and MMP-8 (collagenase-2). In addition to fibrillar type I, II and III collagens, it degrades type IV, IX, X and XIV collagens, gelatin, tenacin-C, fibronectin and proteoglycan core pro-

teins (4, 5, 9, 10). It has been demonstrated that metalloproteinases including MMP-13 are present in gingival tissue explants and that there is an inverse correlation between the loss of collagen fibers and the increase of MMP-13 levels (3). Gingival crevicular fluid proMMP-13 levels have been shown to be significantly correlated with the gingival and bleeding indices (7). Furthermore, it has been suggested that several types of MMPs, including MMP-13 (collagenase-3), play a crucial role in destruc-

tion of periodontal extracellular molecules (28). Thus, it is very likely that MMP-13 is involved in the pathogenesis of periodontal disease.

Prostaglandins (PGs) play important roles in the regulating of diverse cellular functions under physiologic and pathologic conditions (2). In response to stimuli, including interleukin (IL)-1, arachidonic acid released from membrane phospholipid is metabolized to several types of PGs including PGE₂ by cyclooxygenase (COX). Two isoforms of COX, COX-1 and COX-2, have been identified (2, 25). Whereas COX-1 is expressed in many tissues, COX-2 is induced after stimulation by cytokines, growth factors, and lipopolysaccharide and is recognized as an immediate early gene. It is believed that PGs, including PGE₂, are involved in the pathogenesis of periodontal disease (20). Non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit PG synthesis have been reported to prevent periodontal destruction. In particular, PGE₂ has been shown to be a potent stimulator of bone resorption and to be associated with attachment loss (8, 21, 24). Previously, we have demonstrated that COX-2 is responsible for PGE2 production in human periodontal ligament cells challenged with IL-1 α (19). However, the role of COX-2dependent PGE₂ in periodontal ligament cells remains unclear.

Recent studies have demonstrated that the cellular effects of PGE₂ are mediated by the activation of multiple functionally distinct subtypes of PGE2 receptors. These are divided into EP1, EP2, EP3 and EP4, based on their ligand-binding selectivities and signaling pathway mechanisms (14, 15). EP1 receptors are coupled to intracellular Ca^{2+} signaling. EP₂ and EP₄ receptors activate adenylate cyclases via a cholera toxin-sensitive, stimulatory G protein and elevate intracellular cAMP levels. EP₂ receptors are sensitive to butaprost, an agent that selectively binds PGE₂ receptors, whereas EP4 receptors are not. Multiple isoforms of EP3 receptors with different C-terminal tails are generated by alternative mRNA splicing. EP₃ receptor variants mediate several signaling pathways including inhibition and stimulation of adenylate cyclase, activation of phospholipase C and mobilization of intracellular calcium.

Recently, it has been demonstrated that MMP-13 gene is expressed during tooth movement in rats and that PGE₂ down-regulates tumor necrosis factor (TNF) α -induced MMP-13 production in human periodontal ligament cells (16, 26). In the present study, we investigated the effect of PGE₂ on MMP-13 production in human periodontal ligament cells stimulated with IL-1 α . Furthermore, we analyzed which EP receptors were involved in PGE₂ regulation of IL-1 α -induced MMP-13 production.

Human periodontal ligament cells were obtained from explants of periodontal ligaments from premolars or third molars extracted from periodontally healthy subjects. Informed consent was obtained from all subjects. The study protocol was approved by the Ethical Committee of the Tokyo Medical and Dental University. The cells were grown in α-Minimum Essential Medium (α -MEM) supplemented with 10% fetal bovine serum (Bioserum, Victoria, Australia), 100 U/ml penicillin (Sigma Chemical Co., St. Louis, MO), and 100 U/ml streptomycin (Sigma Chemical Co.), and incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2. Cells used for the experiments were between the 5th and 10th passages. Periodontal ligament cells were seeded in 96-well plates for assay of MMP-13 and PGE₂ levels in culture media and in 6-well plates for reverse transcription-polymerase chain reaction (RT-PCR) assay of MMP-13 mRNA, respectively. After confluence, they were serum-starved in α-MEM containing 0.5% fetal bovine serum to reduce the effect of serum on MMP-13 production. After 24 h, the cells were treated with IL-1α (Sigma Chemical Co.), PGE₂ (Cascade Biochem LTD, Berkshire, UK), 17-phenylω-trinor PGE₂ (Cayman Chemicals, Ann Arbor, MI), butaprost, ONO-AP-324, ONO-AE1-329 (gifts from ONO Pharmaceuticals Co. Ltd, Tokyo, Japan), indomethacin and NS-398 (Wako, Tokyo, Japan) in combinations and concentrations indicated. For RT-PCR of MMP-13 mRNA, 24 h after treatment, total RNA was extracted by guanidinium thiocyanate/ phenol/chloroform method, using ISOGEN (Nippon Gene, Toyama, Japan). cDNA primers were synthesized using 2 µg of total RNA reverse transcriptase and oligo (dT) primers (Takara Co., Shiga, Japan). The specific primer pairs for human MMP-13 and β -actin were selected according to previous reports (4, 22, 23). The primers were MMP-13: sense primer 5'-CATTT-GATGGGCCCTCTGGCCTGC-3', antisense primer 5'- GTTTAGGGTTGG GGTCTTCATCTC-3', β-actin: sense primer 5'-GTGGGCATGGGTCATCAGAA-GGAT-3', antisense primer: 5'-CTCC TTAATGTCACGCACGATTTC-3'. PCR reaction was performed in 25 µM of each primer, 2.5 mM of each dNTP and 2.5 units of Taq DNA polymerase (Takara Co.) in an automated DNA thermal cycler. The PCR amplification comprised 28 cycles for MMP-13 of denaturation at 96°C for 30 s, annealing at 55°C for 1 min and extension at 72°C for 2 min. For β-actin, 28 cycles comprising denaturation at 96°C for 1 min, annealing at 60°C for 1 min and extension at 72°C for 3 min the RT-PCR products were resolved by electrophoresis in 1.5% agarose gel containing ethidium bromide. The intensities of obtained bands were determined using SYGENE Bio Imaging System (SYGENE, Cambridge, UK). For assay of MMP-13 and PGE₂ levels, culture media were collected 72 h after cells were treated as described above, and MMP-13 and PGE₂ levels in culture media were analyzed using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Amersham Pharmacia Biotech, Buckinghamshire, UK). ELISA data are expressed as the mean \pm standard deviation (SD). Data were subjected to 1-way analysis of variance (ANOVA), using the STATVIEW program. Fisher's protected least significance test was used in the post hoc comparison of specific groups.

It has been demonstrated *in vivo* that MMP-13 levels are enhanced in periodontal lesions and that several types of cells including gingival fibroblasts and sulcular epithelium express MMP-13 (28). As shown in Fig. 1A and 1B, IL-1 α induced MMP-13 mRNA and protein expression in periodontal ligament cells. It has been demonstrated that TNF α induces MMP-13 mRNA and protein expression in periodontal ligament cells (16). Thus, it is likely that periodontal ligament cells are one of MMP-13-producing cell types.

Previously, we have demonstrated that IL-1a produces PGE₂ via COX-2 in periodontal ligament cells (19). In order to clarify the involvement of COX-2-derived PGE₂ in MMP-13 expression, periodontal ligament cells were treated with indomethacin, a nonselective COX inhibitor and NS-398, a selective COX-2 inhibitor. Both agents significantly augmented IL-1ainduced MMP-13 mRNA and protein expression to the similar extent, although IL-1α-induced PGE₂ production was completely suppressed (Fig. 1A-C). We examined the effect of exogenous PGE2 on IL-a-induced MMP-13 production in periodontal ligament cells. As indicated in Fig. 2A and B, PGE₂ dose-dependently reduced IL-1a-induced MMP-13 mRNA and protein expression. From these data, we suggest that IL-1a-induced MMP-13 production is regulated by endogenous PGE₂ generated via COX-2 in periodontal ligament cells. Finally, we investigated which EP receptors were involved in PGE₂ regulation of IL-1*α*-induced MMP-13 expression using various specific EP agonists. As demonstrated in Fig. 3A and B, 17-phenyl-ω-trinor PGE₂, a selective EP1 agonist, mimicked the inhibitory effect of PGE₂, although butaprost, a selective EP2 agonist, and ONO-AE1-329, a selective EP4 agonist, could not cause significant effects. ONO-AP-324, a selective EP3 agonist, had no effect on IL-1a-induced



Fig. 1. Effect of indomethacin and NS-398 on MMP-13 mRNA expression (A), MMP-13 (B) and PGE₂ levels (C) in IL-1 α -stimulated periodontal ligament cells. A) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence or absence of 1 µM indomethacin (IND) and 1 µM NS-398 for 24 h. After incubation, total RNA was extracted and MMP-13 mRNA expression was examined by RT-PCR. The ratio of MMP-13 mRNA expression to β -actin mRNA expression was calculated using SYGENE Bio Imaging System. B and C) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence or absence of 1 µM indomethacin (IND) and 1 µM NS-398 for 72 h. After incubation, MMP-13 (B) and PGE₂ (C) levels in the culture media were evaluated by ELISA. Values are mean ± SD (*n* = 4). Data are representative of three separate experiments. B: *Significantly different from control (*P* < 0.0001). **Significantly different from IL-1 α alone (*P* < 0.0001). C: #Significantly different from control (*P* < 0.0001). ##Significantly different from IL-1 α alone (*P* < 0.0001).



Fig. 2. Effect of PGE₂ on MMP-13 mRNA and protein expression in IL-1 α -stimulated periodontal ligament cells. A) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence of 1 μ M indomethacin (IND) and various doses of PGE₂ for 24 h. After incubation, total RNA was extracted and MMP-13 mRNA expression was examined by RT-PCR. The ratio of MMP-13 mRNA expression to β -actin mRNA expression was calculated using SYGENE Bio Imaging System. B) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence of 1 μ M indomethacin (IND) and various doses of PGE₂ for 72 h. After incubation, MMP-13 levels in the culture media were evaluated by ELISA. Values are mean \pm SD (n = 4). Data are representative of three separate experiments. *Significantly different from control (P < 0.0001).

MMP-13 expression (data not shown). These results suggest that PGE₂ regulation of IL-1*a*-induced MMP-13 expression is mediated via EP1 receptors. It has been shown that TNFa-induced MMP-13 production is inhibited by cAMP in periodontal ligament cells (16). However, butaprost and ONO-AE1-329 could not affect IL-1ainduced MMP-13 expression, suggesting that IL-1α-induced MMP-13 production is not regulated by cAMP-dependent pathways through EP2 and/or EP4 receptors. It is likely that TNFa- and IL-1a-induced MMP-13 production is differently regulated in periodontal ligament cells. Further studies are necessary to elucidate the mechanism by which PGE₂ inhibits IL-1a-induced MMP-13 expression via EP₁ receptors in periodontal ligament cells.

In the present study, the roles of MMP-13 were not investigated in periodontal lesions. MMP-13 has been detected in gingival crevicular fluid and gingival tissues from patients with adult and localized juvenile periodontitis (6, 7, 28). It has been shown that MMP-13 is involved in collagen breakdown in periodontitis (3, 6, 29). It has been demonstrated that there is the possible association of vertical bone loss and elevated MMP-13 levels in periimplant sulcus fluid and that MMPs including MMP-13 are associated with bone resorption in mouse calvaria (11, 12). Therefore, it is very likely that MMP-13 is involved in the pathogenesis of periodontal disease. In the present study we showed that PGE₂ inhibited IL-1a-induced MMP-13 production in periodontal ligament cells. PGE₂ has been shown to be a potent stimulator of bone resorption and to be associated with attachment loss (8, 21, 24), and is therefore thought to mediate proinflammatory and tissue-destructive responses in periodontal lesions. However, several studies have demonstrated that PGE₂ suppresses the production of proinflammatory molecules, including intercellular adhesion molecule-1, IL-6. chemokines and TNFa (13, 17, 18, 27). Together with our data that PGE₂ inhibited IL-1a-induced MMP-13 production in periodontal ligament cells, we suggest that PGE₂ may exert anti-inflammatory effects in periodontal lesions. Further investigation is required to define the roles of PGE₂ in periodontal disease.

In conclusion, we suggest that COX-2dependent PGE₂ can down-regulate IL-1 α elicited MMP-13 production via EP₁ in human periodontal ligament cells. PGE₂ may be involved in the regulation of destruction of extracellular matrix components in periodontal lesions.



- Noguchi K, Iwasaki K, Shitashige M, Endo H, Kondo H, Ishikawa I. Cyclooxygenase-2-dependent prostaglandin E₂ down-regulates intercellular adhesion molecule-1 expression via EP₂/EP₄ receptors in interleukin-1β-stimulated human gingival fibroblasts. J Dent Res 2000: **79**: 1955–1961.
- Noguchi K, Shitashige M, Endo H, Kondo H, Ishikawa I. Binary regulation of interleukin (IL)-6 production by EP₁ and EP₂/ EP₄ subtypes of PGE₂ receptors in IL-1βstimulated human gingival fibroblasts. J Periodontal Res 2002: 37: 29–36.
- Noguchi K, Shitashige M, Ishikawa I. Involvement of cyclooxygenase-2 in interleukin-1α-induced prostaglandin production by human periodontal ligament cells. J Periodontol 1999: **70**: 902–908.
- Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE₂ secretion as a determinant of periodontal disease. J Periodontol 1993: 64: 432–444.
- Offenbacher S, Odle BM, Gray RC, Van Dyke TE. The use of crevicular fluid prostaglandin E levels as a measure of the periodontal status of adult and juvenile periodontitis patients. J Periodontal Res 1984: 19: 1–13.
- Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucl Acids Res 1984: 12: 1687–1696.
- Ravanti L, Heino J, Lopez-Otin C, Kahari VM. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1999: 274: 2446–2455.
- Shelling SH, Wolfe HJ, Tashijian AH Jr. Role of the osteoclast in prostaglandin E₂ stimulated bone resorption. Lab Invest 1980: 42: 290–295.
- Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001: 107: 1491–1495.
- Takahashi I, Nishimura M, Onodera K, Bae JW, Mitani H, Okazaki M, Sasano Y, et al. Expression of MMP-8 and MMP-13 genes in the periodontal ligament during tooth movement in rats. J Dent Res 2003: 82: 646–651.
- Takayama K, Garcia-Cardnas G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P. Prostaglandin E₂ suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002: 277: 44147–44154.
- Tervahartiala T, Pirila E, Ceponis A, Maisi P, Salo T, Tuter G, et al. The *in vivo* expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res 2000: **79**: 1969–1977.
- Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, et al. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol 1998: 152: 1489–1499.

protein expression in IL-1 α -stimulated periodontal ligament cells. A) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence of 1 μ M indomethacin (IND) and 1 μ M 17-phenyl- ω -trinor PGE₂, butaprost and ONO-AE1-329 for 72 h. After incubation, MMP-13 levels in the culture media were measured by ELISA. Values are mean \pm SD (n = 4). Data are representative of three separate experiments. *Significantly different from IND + IL-1 α (P < 0.005). B) Periodontal ligament cells were stimulated with vehicle or 2 ng/ml IL-1 α in the presence of 1 μ M indomethacin (IND) and 1 μ M 17-phenyl- ω -trinor PGE₂, butaprost and ONO-AE1-329 for 24 h. After incubation, total RNA was extracted and MMP-13 mRNA expression was calculated using SYGENE Bio Imaging System.

References

- Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995: 7: 728–735.
- Dewitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991: 1083: 121–134.
- Ejeil AL, Igondjo-Tchen S, Ghomrasseni S, Pellat B, Godeau G, Gogly B. Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva. J Periodontol 2003: 74: 188–195.
- Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994: 269: 16766–16773.
- Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996: 380: 17–20.
- Golub LM, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, et al. A matrix metalloproteinase inhibitor reduces bonetype collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997: 46: 310–319.
- Kiili M, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, et al. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol 2002: 29: 224–232.
- Klein DC, Raisz LG. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 1970: 86: 1436–1440.

- Knauper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 1997: 272: 7608–7616.
- Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP, et al. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem 1996: 271: 28509–28515.
- Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998: 139: 1338–1345.
- Ma J, Kitti U, Teronen O, Sorsa T, Husa V, Laine P, et al. Collagenases in different categories of peri-implant vertical bone loss. J Dent Res 2000: **79**: 1870–1873.
- Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E₂ inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997: **122**: 149– 157.
- Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999: 79: 1193– 1226.
- Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995: **1259**: 109–119.
- Nishikawa M, Yamaguchi Y, Yoshitake K, Saeki Y. Effects of TNFα and prostaglandin E₂ on the expression of MMPs in human



Fig. 3. Effect of 17-phenyl-ω-trinor PGE₂, butaprost and ONO-AE1-329 on MMP-13 mRNA and

в

This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.